Filing Analysis
Voyager Therapeutics held its 2026 Annual Meeting of Stockholders on June 9, 2026, where shareholders approved a significant increase in the number of authorized shares of common stock. The company also elected Class II directors and ratified its independent auditor.
🚩 Red Flags
- Significant increase in authorized shares (doubling the common stock from 120M to 240M) often precedes dilutive equity offerings to raise capital.
📋 Key Facts
- Authorized shares of capital stock increased from 125,000,000 to 245,000,000.
- Authorized shares of common stock increased from 120,000,000 to 240,000,000.
- The Certificate of Amendment was filed with the Delaware Secretary of State on June 9, 2026.
- Stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D. as Class II directors.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Voyager Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for VY1706, a tau silencing gene therapy for Alzheimer's disease. The company intends to begin a multi-site, open-label, dose-escalation clinical trial in the second half of 2026.
📋 Key Facts
- FDA cleared the IND application for VY1706 on June 1, 2026.
- VY1706 targets both intracellular and extracellular tau for Alzheimer's disease (AD).
- Clinical trial dosing is expected to commence in the second half of 2026.
- The study will enroll up to 18 adult participants with early AD and confirmed tau pathology via PET imaging.
- Primary endpoint is safety and tolerability; secondary endpoints include CSF biomarkers and tau PET imaging changes.
- Maximum dose will not exceed 5 x 10^13 vector genomes per kilogram.
Voyager Therapeutics announced its first quarter 2026 financial results and provided general corporate updates. The announcement was made via a press release furnished as Exhibit 99.1.
📋 Key Facts
- Announcement of Q1 2026 financial results on May 7, 2026.
- Corporate updates provided in conjunction with financial results.
- Filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
- The report was signed by CEO Alfred Sandrock, M.D., Ph.D.
Voyager Therapeutics announced the resignation of CFO Nathan Jorgensen, Ph.D., effective May 8, 2026. The company has appointed current COO Robin Swartz as Principal Financial Officer and VP of Finance Amy Quinlan as Principal Accounting Officer to assume his responsibilities.
📋 Key Facts
- Nathan Jorgensen, Ph.D. resigned as CFO on April 15, 2026, effective May 8, 2026, to pursue a new opportunity.
- Robin Swartz, age 55, currently the COO and Chief Business Officer, will become the Principal Financial Officer and Treasurer.
- Amy Quinlan, age 51, currently VP of Finance, will become the Principal Accounting Officer.
- The company stated there were no disagreements with Dr. Jorgensen regarding operations, policies, or practices.
- Robin Swartz has over 10 years of finance experience at Sanofi Genzyme prior to joining Voyager.
Voyager Therapeutics reported its fourth quarter and full year 2025 financial results and provided corporate updates on March 9, 2026.
📋 Key Facts
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report covers the fiscal period ending December 31, 2025.
- A press release detailing the financial and operating results was furnished as Exhibit 99.1.
- The report was signed by CEO Alfred Sandrock, M.D., Ph.D.